What is Positron?
Positron Corporation is a dedicated player in the nuclear medicine and healthcare technology landscape, with a primary focus on cardiac positron emission tomography (PET) imaging. The company provides a comprehensive suite of products and services, including PET molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, and radiopharmaceutical processing and production. Its flagship Attrius system leverages cardiac PET technology to enhance the accuracy of heart disease diagnosis, aiming to improve patient outcomes and promote cost-effective medical practices. Positron is also actively involved in increasing the supply of Sr-82, a critical radioisotope, through processing and recycling efforts, underscoring its commitment to the advancement of nuclear medicine.
How much funding has Positron raised?
Positron has raised a total of $33.6M across 4 funding rounds:
Debt
$66K
Multiple Rounds
$33.5M
Debt (2021): $66K with participation from PPP
Angel/Seed (2025): $23.5M led by Flume Ventures, Valor Equity Partners, and Atreides Management
Share Placement (2025): $8M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Key Investors in Positron
Flume Ventures
Flume Ventures is a network of seasoned operators and founders dedicated to partnering with visionary entrepreneurs to scale bold ideas. The company provides guidance, mentorship, and a trusted community, leveraging the experience of its founders who have built category-defining businesses.
Valor Equity Partners
Valor Equity Partners provides financial services to businesses in the scope of investment activities. This company is headquartered in Chicago, Illinois and was established in 2001.
Atreides Management
Founded in 2019 and headquartered in Boston, Massachusetts, Atreides Management is a company that focuses on long-term investment for companies in the technology and consumer businesses in both public and private markets.
What's next for Positron?
The recent major strategic investment in Positron indicates a strong market confidence in its specialized technology and its potential to address critical needs in cardiac diagnostics. This capital infusion is expected to fuel further research and development, potentially expanding the company's product offerings and market reach. Strategic partnerships and continued innovation in PET imaging technology will likely be key drivers for Positron's future trajectory. The company's efforts to secure and optimize radioisotope supply chains also suggest a forward-thinking approach to ensuring the long-term viability and scalability of its operations, positioning it for sustained enterprise-level growth.
See full Positron company page
